BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: The dual-luciferase experiment validated Bcl-2 as the direct target of miR-153–3p The reduction of miR-153–3p in resistant patients, together with the accompanying elevation of Bcl-2, may mitigate therapy resistance, as research on CML have demonstrated that heightened Bcl-2 might diminish apoptosis and facilitate drug-resistance [165].